A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.
This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...
Ionis Pharmaceuticals, Inc. shows promise with new drug launches and a robust pipeline. Click here to read IONS stock ...
11hon MSN
The Inflammation Gap
Popular ideas about inflammation have lost touch with medical reality.
People with prediabetes experience impaired insulin release and insulin resistance, explained Priya Jaisinghani, M.D., an ...
Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.
PCSK9 inhibition may be a suitable alternative for statin-intolerant patients, and recent data demonstrated its efficacy as ...
Currax Pharmaceuticals LLC ("Currax"), a pharmaceutical company that delivers life-changing medicines to patients with chronic, progressive diseases, today announced that leading obesity experts will ...
Cirius Therapeutics, Inc., a developer of innovative therapies for people suffering from diseases caused by insulin resistance and metabolic dysfunction, will be presenting new data today at ...
The Trump administration plans to announce a deal with pharmaceutical companies to sell discounted weight-loss drugs through ...
There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback